In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples